PSTV - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics First Quarter 2022 Results Call. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. [Operator Instructions].

Before we begin, we want to advice you that over the course of the call and question-and-answer session, forward-looking statements will be made regarding events, trends, business prospects and financial performance, which may affect Plus Therapeutics’ future operating results and financial position. on subject described and section filed under Plus annual are risks including included with statements quarterly time. Therapeutics’ uncertainties and Exchange and the reports time the such Securities to Form Commission uncertainties, risks the in reports and All on XX-K from XX-Q to Form Risk Factors factors statements. such Therapeutics you Plus considering advises to in review these risk the trends date revise assumes are any update forward-looking or no circumstances reflect to Therapeutics after Plus or events, they made. responsibility statements to It my to to the Dr. turn is pleasure now floor over Plus Marc President Hedrick, Therapeutics’ Officer. and Chief Executive may you Sir, begin.

Marc Hedrick

very our Good to once join you first results. XXXX business an everyone. time again as today Thank recent we provide quarter financial Thank you much, Gretchen. us overview the discuss for and taking of afternoon, highlights

progress today recent call turning on for XXXX. Despite Officer. Chief very our Andrew throughout financials. with be our is since Norman Andrew continue LaFrance, Officer; progress commentary provide call clinical and Financial our short before Norman corporate me clinical Medical on overall the the by Dr. we our work I and meaningful over following as several Chief Joining catalysts to reviewing then our and interval results, review last the will we pleased Norman, to towards who XXXX. Sims, will reported the And I’ll begin call quarterly our progress milestones

is without RNLXXX MTD, LM escalation dose, a our to patients LM. MFD breast diagnosed the in X/Xa approximately trial only maximum the respectively. or Phase and autopsy. patients enrolling few During XXXRNL about quarter, XX%. efficacy with and safety The annual and patients in cerebrospinal patients these growing, of leptomeningeal no and the X%, LM and given with impairment in ReSPECT-LM standard to complication is LM. FDA-approved XXX,XXX which are at that multi-center LM the weeks. cancer, began months aggressive and neurologic one treatment Survival to fluid U.S. either on with fluid. external rise a common the tolerated study two-year of eight-and-a-half about depending the and rate is is includes we current associated structures and first directly gastrointestinal in dose survival intravenously There treatment are prevalence determine even primary is by or treatment followed incidence metastases, X% system with employed cancers cancer, of malignancies. sites, therapies chemotherapy affect the or trial and a and in the X% tumor Most of the leptomeninges. about of tumors is patients orally is into lung to radiation survival XX% that cancers of Median beam fatal three typically melanoma, is LM central is therapy affected giving nervous line or advanced caused

from XXXRNL. Although single initial outcome first we the limited with a we’re pleased very only receiving patient draw can the administration experience, conclusions and of our

XX% very being six preliminary as very one patients, in that gets so a sites at and radiation reduced treatment. that throughout released we’re a the XXXRNL Phase leptomeninges tumor found excited exhibited is fluid for by was rapidly CSF we this drug with in about result. We found after events, circulating Specifically, cerebrospinal adverse week counts the patient through We have now active X sites the no two as least trial, circulated first-in-man cell first speak. and space. The as really weeks onboarded, treatment. we another -- it over screening This good after two at about LM patient

more have to at bit than XXXX, completed and by cohorts two the track end hopefully of a least on We’re first that. the

in XXXRNL recurrent As updates. to for our have glioblastoma, development a number of we ongoing clinical program

annually of reminder, for as NCI. cohort it’s study significant U.S. GBM. sequential Glioblastoma about National glioblastoma dose most open challenge. and and the First, in lethal label unmet may the of you medical escalation very The volume and or trial disease a brain many as of of same by and common Health affects devastating remains multi-center cancer of a a funded is to degree, recurrent U.S. number XX,XXX the EU, in know and X/Xa patients Phase the trial patients and significant Institutes dual a that about the form treatment is this currently

limiting and presented appears In be terms to tolerated, on XXXRNL mild-to-moderate of recently the in data be found and RNL-related. in and no been dose Generally not safe well and and treated SAEs, been can accessible all been detail three are AEs back our toxicities or be to most seen deem anyone. In data, in clinical lower observed. summary, grade have to most this have seven website XX have that’s patients March

to drug we and now over XXX get terms in of achievable radiation well able empirically-determined is delivery dose is think In can tumors, of threshold XX% we XX% are XXX absorbed absorbed gray. deliver we adequate of terms over radiation, delivery, reliably dose to reliable our of which dose of gray minimal and

bevacizumab. size. survival big monotherapy exceeds explain rate like tumor I’d have published signal on we plan observed the on for the our plan GBM to data, and Finally, We the both that plan. median Based based clinical this development bifurcate just current overall picture to mean best

of dose. and tumors our Phase recommended in XX volume, X about to XX.X the which first registrational glioblastomas, XX So plan recurrent to CCs CCs of all about represents millicuries as six use X.X volume two-thirds approximately one-half to we of for of cohort dose

size of X/X larger we DLTs have our volumes, dose the In to radiation for potentially trial GBM, dose-limiting greater upper we regulatory and treatment intend milestones. two of continue requiring or establish Phase dose tumors for dosages potential For to escalation and XXXX, key toxicities. limits

excellent specifically FDA already package a to in Type registrational our trial. GMP progress two C the activities. our a asked make have And then for development, manufacturing support drug CMC and the in XXXRNL for to CMC determine meetings, and to our of scale-up We CMC relatedly team to the XXXX meeting sufficiency of submitted continues first

Specifically, on to The the activities manufacturing support development drug trial X activities Phase track thereafter. remains registrational company company RNL finalized to deliver commercialization our planned mid-XXXX. and characterization key RNL for has and GMP GMP by

as trial FDA The key focused QX, completed is X QX CCs planned XX.X solicit meeting second we FDA a milestone. our Phase meeting planned to and Phase X on clinically a less recommended X using Also for little dose our millicuries during QX, another than mentioned feedback volume. of registrational

X the trial randomized a registrational broad trial to FDA been existing use the for clinical incorporating the X/Xa partnership planned mentioned the in its trials of Phase effective FDA Synthetic with Medidata RNL already we a entered World glioblastoma. also with will registrational Real or Arm far facilitates fewer trial. has as enrollment trials. in control platform might life advancement, by Phase data used Synthetic the recognize meeting and time of our use Specifically, therapies. And Besides design and to agreed we that escalation patients Control Phase greater them primary partnership a extending a with successfully FDA although recurrent as X be above, that historical continued to completed allowing arm care X/Xa develop recent and exposed to to treated Arm data in GBM, It proposed Phase our reduce the the rare access Phase initiating for data our as trial. These for platform registrational or in and More glioblastoma, our has and be control to diseases a patients continue. received generally, manner placebos clinical thus an treatments X in will support clinical favorably FDA. Control group not goal SCAs for them. and cost registrational complex to comparators end-of--phase be SCA standard preliminary That evaluation patients with planned such GBM recurrent SCA potentially is the that X associated trial, this compliant Phase dose glioblastoma in an I trial phase of identical The of our into and to the offers

of to a Finally, in this quarter, open extension we recurrent RNL Phase glioblastoma. trial multi-dosing X intend

not As us these important is give company, and glioblastoma cure the disease in to the notoriously trial multiple follow goal determine curing help to using important utility paradigm chronic the trial. about big initial extension overall following with patients for in trial returning you we of disease recurrent of into This previously know, our it difficult in doses the will administration potential is This live which of really information brain done efficacy safety, and of we the day, RNL of single if patients is patients. The One of you treatment the dream. if feasibility XXXRNL doses norm. potential RNA in to as the Phase X/Xa additional have is a GBM, the cancer.

license QX, our technology Finally, of we in of the a microparticle Texas. from novel announced University radioembolic

transaction times, killing of for for potent the damage builds radiotherapeutic use of longer believe This that rare irradiating technology XXX not problems the a It Rhenium-XXX and focus quality and blocks in high the also of Liver energy XX a primary BAM radioembolization with XX%. to cancer our rate cancer the future a is said to we next-generation characteristics many will annual is tumors tissues. upon the the is with a been particle short, technology therapy BAM As or we’ve human liver tumor targeting cancer therapy normal resorbable path the and existing can precise liver leverage half there minimizing Biodegradable BAM agents with that about And Rhenium-XXX a but millimeters. It of any we The the highly out in in standard most criteria as produces XXX we embolic decades. providing admission incidence biomaterial body life segments fully with energy coupled organ. generation incorporates next Alginate using as interventional X hepatic this solid we a breadth about different embolization, supply radiotherapeutic artery radioembolic radiologic solves almost localized technology, blood tumor the only high overall is technology opportunity beta NanoLiposome Rhenium of hours technology. which isotope, many developing current use BAM organ than technology, call NanoLiposome also with disease billion cancer a existing emits X.X resorbable increasing just target and for with with new RNL-BAM cancer real-time system. a the over Rhenium-XXX, means isotope Microspheres the with The the technology potent that the source XXX. can vascular of directly five-year BAM tumor. the gamma that’s about for or of many malignant length imaging radioembolization secondary only company The in construct radiotherapy an for for global initially a on survival opportunity globally. chemoembolization, for by the while while of

has for which have on we We feasibility objectives technology the key three been pre-IND IND-enabling program; to this phase, XXXX and completed our complete FDA CMC and in an studies, preclinical cancer BAM studies meeting track year. are

the over I’ll Norman? So Dr. turn call with LaFrance. to that,

Norman LaFrance

you, Marc. Thank

Following NDA the has clinical Pending recurrent potential doses gray with XXX patients we FDA planned be for initiate than In on be the extend efficacy trial safety Phase trial in profile meetings achieve will first this XXXX will earlier. ready overall The milestone. and a its X trial mentioned Marc registrational of is plan plan; the absorb year-end. sites clinical outcome and to Phase our first using importantly recommended that six in to approvable our doubling to an two our Marc’s ReSPECT-GBM clinical to development interim, for the the existing of into advisors planned dose GBM be operations our key cohort FDA ReSPECT-GBM company a the the comments, GBM. and strong meetings, most by survival and potential radiation greater X we development of plan program -- that registrational believe signal in the the executing

patients trial for NCI tumors. and by multi-dose trials X Second X be extension in is third And that just the two the Phase dose continuation treated supported treated escalation will for of trial mentioned. Phase patients is the larger a previously

Meeting the medical XXXX, key June to of GBM SNOW August; Nuclear data the Toronto November. for Brain EANO potentially in & GBM Vancouver; Medicine and terms plan of Mets and Meeting following both in clinical in in Society Meeting Clinical Tampa in Barcelona SNOW Paris, Annual and in we ESMO in the Trials September; at In respectively, in provide updates meetings: the this ASCO-sponsored in presentations Vienna October; EANM and

Medidata next Industry Control Arm on Additionally, Focused I’ll XX. Roundtable Synthetic the April week be at participating

as were with our also simple few but number feedback in in CSF, we the of of in Phase exciting, X existing many had is measuring as the delivery investigators the the in tumor a patient is the and we patients. As from first five-minute well. looking biomarkers Ommaya Treating are any response first biomarkers experienced at The in substantial condition to a which very which very that trial an an with the patient one investigators trial. team and they outpatient There very cell comments. investigational straightforward never seen clinical of drug unknown. reservoir. this such A ReSPECT-LM is with exploratory such outcome Marc trial count, There first-in-man are additional the mentioned, an simple obtain patient existing The always of RNL are pleased trial. these clinical are first new procedure was with through in

patient perform Additionally, first Despite multiple evaluate preclinical with and both will treatment impressive Plus with checkpoint doses monotherapy, to with initial single optimal a paradigms treatment combination results amplified as Plus multi-dose and/or several administrations dose synergistic at combination RNL therapies. such XXXRNL, with can the RNL inhibitors, and be studies immunotherapy PARP additional with be believes specifically radiation. LM known to benefit

approval received and ago. a data investigative RNL brain we current clinical trial, here of later finally, the meeting Lurie once our to of dose with the goal medical significant is is and along rapidly from and site, year. IND planned enrollment for the were use hear For need, minutes Children’s well XXXRNL to presented very based in with XXXX enthusiastic administration Hospital clinical responses children medical obtain few being cancer optimistic FDA oncologists trial. milestone with track tolerated to are on our sites, LM investigate other The on pediatric developed lead unmet cancer. are key working this for proceed And will in preliminary Chicago our and hit Developing this they I’m presentations brain easy and for

review to our financials. you, floor to Andrew the turn I’ll Next, will Over Andrew. CFO, Sims, who

Andrew Sims

the of first Thank XXXX. release everyone. you, a Please refer results financial Norman, earlier to ended and press quarter for our good our summary XX, issued for afternoon, today XXXX March

cash and intellectual quarter in quarter XXXX. or and $X.X XXX,XXX on for $X.XX cost equivalents million, three first were fees the $XX.X Cash to turn the to a decreased paydown of for million, expenses back and net XXX,XXX of March of XXXX in that first $X.XX to $X.X loss expenses to million Net due XXXX. of the $X.X December million $X.X XX per share, $X.X of or legal, the used of per decreased principal follows. the $X.X is in to quarter million As operating loss compared debt. increase And million compared million you, of between of of XXXX Interest in $X.X as quarter development operating I’ll professional total million ended Approximately expenses from million and commenced The to quarter XXXX in XX, was for ‘XX the XXXX. main Marc. first Total Oxford XX, quarter compared XXXX, compared cash the the for it first represents first of and to the to the XXXX. expense for XX this was November as first reflects This were of first XXXX. quarter XXXX property March XXXX XX, $XX.X to $X share months now, XXXX. due XXXX months is hand. This cash research in operations million on changes

Marc Hedrick

Great. Thank Andrew. you,

key we on Q&A, summarize milestones for move to Before XXXX. just let anticipated me

trial using X X.X/XX.X cohort respect millicuries and a registrational dose, detailed with the Phase focused we’re for planning propose the clinical XXXX trial, as First, design six mid-year to a GBM to earlier. meeting trial XXXRNL clinically FDA

meeting initiate second anticipate third to the time. end CMC that perhaps clarify, that’s of year. focused of towards to to that the the beginning in open XXXX issues FDA quarter. expect quarter We of resolve the CMC And We exist Phase the the X may at any the or

trial. important to have Regarding we very drug drug availability, that proceed availability GMP with the

X/X We’re least at is updates for plan to in on with We cohorts as ongoing two trial our and that manner, and in by RNL. activities complete goal we’ll this drug CMC have the an ready data track ReSPECT-LM year. enrollment X supply Phase complete Phase to enrollment available report Also XXXX, initial in mentioned, for those Norman GMP and mid-XXXX.

tumor brain submitted year IND trial our relatively able be soon pediatric the year. end plan the towards of Regarding that get to and initiate we the trial, this to

complete XXXRNL-BAM and recently also Regarding FDA this to acquired technology, therapy we a radioembolization key plan meeting and studies our the rights CMC to IND-enabling year. pre-IND

So at to Gretchen, think that over move Q&A, to I and back I’ll turn call Gretchen. to point, you. the we’ll

Operator

you. Thank Instructions]. [Operator

Ed Woo Our from first coming question from Ascendiant. is

Your line open. is

Ed Woo

wondering have longer planned Do for or Thanks I expect? than post-COVID, is do bit that to year. if the normal little with taking possibly running possible question. you you know couple of this a still timing delays has my you that was reverted there’s meetings FDA you a see back

Marc Hedrick

you answer would that? Norman,

Norman LaFrance

but weeks provide I’m great question. these and until four Ed, anticipating follow date XX three days. meetings, FDA their meaning within meeting by gets guidance to the usually answer We that’s a know they’ll won’t back an they’ll us, for published probably or

as they dates those guidance sooner those have the than than PDUFA were out be you in not usual anticipating occurring the right earlier know, they pandemic. the I’m But As to them. move actually requires up to further meeting pushed

Ed Woo

And get trial trying you additional other guys funded you that some of the are is question GBM these last Great. funding Thank anticipate my current then on? to by for is NIH. working your Do indications you.

Marc Hedrick

to so been you’re oncology-related I they Ed, fund obtaining they Texas we’re aware. Phase because to programs. for know based X. opportunities interested Phase we’ve one grants, That’s typically Unfortunately our various trials, in Phase program, the is will are reasons very as CPRIT GBM of And CPRIT. don’t but the funding there Texas-specific X fund X for called in

something funding definitely will CPRIT two there, So that’s year. Where we’re interest. plate at and up with that’s continue be to a the cycles of

ways non-dilutive CPRIT. And to so like of obtain we lot a spent find funding trying time to

So we’ll as get once commend. we if we’ll our approved that about previous won’t we continue specific But talk to and once plan, do grants that. notified. talk we’re But we funded, per about and something we certainly

Ed Woo

Well, you, you. thank Great. guys and wish Thank good I you luck.

Marc Hedrick

Thank you.

Operator

Lee Instructions]. Sean take our H.C. [Operator We’ll Wainwright. from question at next

Sean Lee

This to the penetration one larger first Lee It’s LM that my face intrathecal chemotherapy is to on solid with first chemotherapy for of is great Wainwright. into they Thanks all that issues H.C. is the the – the is treat patient tumors. – from well. LM, taking that hear traditionally is doing there Sean guys My questions. study. but And drug insufficient

wondering was well. potentially guys RNL is you face something as I that with that could So

Marc Hedrick

question. great Sean, Hey,

types. be the So sort it’s is linear focal disease, have on can millimeters of the whereas linear lining in nodular there’s One very few be thin, disease, with leptomeninges. and but which leptomeningeal the of just tumors two a more nodular. can other is The you

length, penetration path within closer delivered So the has about it up CSF. is RNL that a things to X a of of X millimeters, some sort excited path with average length have characteristics. one as have does the we’re to with it It’s millimeters. about path lengths can but background, of It

penetration disease. nodular some can well in you linear as the actually hitting disease So as get

limitations LaFrance he maybe effect in So radiotherapeutic. anything some chemotherapy of would some better chemotherapy of this I of to the of we has benefits than Dr. if And that he’s add. the CSF, expert solicit the as think and of an because a have could see

Norman LaFrance

have disease administered the is the Whether to leptomeningeal I chemotherapy design getting And unique you’re membrane of CSF-administered unfortunately think LM even subarachnoid you has these and challenge there. patients spread complication metastases the along leptomeningeal really it’s space. a study the of this great the absolutely right. question. one and the of systemically tragic throughout And chemotherapy, characteristics

rapidly. in So on have it intrathecally, the And your observation. you spot it when CSF escapes that doesn’t administered usually very --

turnover CSF, times As a the you about which of of know, the a ml volume may five XXX day. volume is has

product the outpatient the And of we that administration time only alluded of So objective CSF kind they the needle. procedure. to over circulations. you distribution there over evidence, at predicted space quickly excellent of the Marc it’s aware but which we don’t pediatric side XX-gauge time out nanoliposome beginning circulation RNL very you Rhenium-XXX design, disintegration in Patient is because use as over seen Ommaya really Think in easily administration there a a staying administered little have period. in on goes -- Marc get is have heard evidence need, physiology. the of that imaging gamma we very It subarachnoid duration through even five-minute They of The band-aid described, an week. call, even that it. and something for gets the in as it with have a physiology the that comments skin exits the his a of not in Ommaya, of RNL it’s a not We band-aid the over with also the shunt. ray simultaneous butterfly

dose, of probably we benefit very first why kind is – – X this very this they dose, during And small our at by a energy you basically millicuries early time. stays of of get full hindsight, full So In decay the result particle life which and of you its get four there response. benefit that half administration. or product instead product this that’s three this given effective period, and whole at saw get the kind life, the half

this has before. surprised. I our he one of I And we never think as were where that’s mentioned, investigators, pleasantly experienced seen

you. thank So

Sean Lee

kind to place deliver a second delivery. Thanks, you’re the a slightly method you’re of GBM radiation study? what to It’s helpful. My question different Marc, LaFrance. on and very thanks, is compared using LM, that that able Would dose of limit Dr. with because

Marc Hedrick

benefit the I because that’s question, easy. the actually so that in LM makes it appreciate delivery of

of having doing deliver part question, your that dose we’re we of will dose find really administer we dose But next the So answer trial, next our asset we’ll guess our the to quicker the doubles and -- and escalation it will I amount cohort instead go that to be the out. the -- cohort doubles is going again.

by have by we four we’re year-end, the – using we’ll So experienced hope times at dose now.

the we dosing to the first dose and delivered issue. work the I going on given an will therapies, preclinical start response patient we’re administered Given saw don’t on amount nation multiple of therapies or the be think

absolutely it delivering few an a So That albeit this CED to required we’re differently. you’re turns correct opposed that process inpatient, the only days therapeutic the as delivery. actually outpatient for into

Sean Lee

great And later results is my hear certainly year. the forward upcoming the this Phase question X to and looking GBM to study. final on That’s

prepare than able other before the part as well, study? need you’re and the for that CMC initiate So what you to else company to does the so waiting FDA meeting

Marc Hedrick

actually. I’ll an know saying what give overview. you’re I

cost. of a So decreasing Synthetic Control the is enrollment it only in making randomization to but the That’s part our important we need big – of going more the be patient work developing is and Medidata terms with trial, also to Arm. the not what part the of maximizing in an do, scheme, friendly, Sean,

we’ve with -- done feasibility assessment a them. that’s So already

of lot sense the feasible. That We have that trial. a a that developed go will into and will it’s soon here strong be relatively

really plan the meeting than I so the forth, protocol that, and preparing think and mean. package of progress. you synopsis it’s the what are just all and statistical those in that’s analysis Other in

Norman LaFrance

We the have benefit the trial. of ongoing

go Sorry, ahead.

Sean Lee

that’s FDA special as get No, study? to follow-up, wondering good seek assessment the a would with this the protocol hear. company to a I’m quick for just

Marc Hedrick

that know don’t about that? thoughts honestly. I we need one, do any have you possible. It’s Norman,

Norman LaFrance

That’s a to great look question. the People always SPA.

would have approach, being that potential and FDA disease, Synthetic have a for the Given time. special a certainly therapy to to protocol add we the actually Getting you Control there. already our rare breakthrough Fast Track orphan usually assessment, go Arm probably this is

signal, very in has as FDA that in given arm shape GBM, possible proceed very precedent about at we’re in good preliminary control the particular. as have, accepted given So drug to in being already solid what rapidly efficacy a given we for development,

So meetings agreement, and kind by an FDA require to SPA, I and interactions negotiations. we’ll some We and by third year-end. of the be believe and quarter have think would additional summer, have sites would redundant initiated be able an

correct very first, possible. that we it we’re interact but fastest doing have the to FDA with You’re way

Sean Lee

for that’s I the have. and that, see. questions Thanks all I

Marc Hedrick

Thanks, Sean.

Operator

[Operator Instructions]. And it further I time. have turn appears Andrew to at now this no will Sims. floor over questions back the we

Andrew Sims

have Thanks, in was trial. the I on emailed GBM a question Gretchen. that

working trial including Phase is, trial you question sounds can towards it details end the So GBM like a of you’re patient registrational provide the X on What XXXX. the towards numbers? about design,

Marc Hedrick

about what some it. can’t level that point this course, confidence I there’s on the we’re a So think I definitively Everything is thinking you to haven’t answer dependent, we’re FDA, the close. is of tell we anything pretty can at how FDA you And give guidance the reasonable as because talked to of pretty but says. I

registrational of have trial said number possible with patients. before, successful of terms So as in we a to think it’s XXX patients, we

We’ll Primary FDA. after we’re endpoint think more be and between to will XXX the know patients. to talk be going XXX I overall we survival.

more And clear. see that’s a a you that typically GBM think I or the scheme, randomization randomization. is scheme randomization rare X:X disease, goal X:X trials. for typically in On might

get and before is done Synthetic you’re the one who of patients control X:X:X patients where perhaps, One a the likely which group the Control then has Arm randomize come it’s three from your that actually treated the benefits Control randomization two arm. patient you Synthetic in like the been where control scheme and of Arm,

up good ethically for end getting out these patients four of So for three enrollment good which very and patients. treated, is

that cost and would so So forth. help and funding certainly

Control of Synthetic can we’re which perspective, aren’t So preference, an I it’s are against which good we’ll options. is like likely of more and very a standard These sink no control something think what a because On clear kind to patients go kitchen something Arm there that, really approach. is that there’s these hoping comparison in provide. extreme care. a get, patients essentially That’s MD situation

are particularly budget closer I million. pretty think So to and size, in probably to trial what else? perspective, $XX Arm and closer good a therapeutic sites is world-class what that know respond are in most a Synthetic terms the to million – from end of we number of been with in enroll be sites XX Control XXX close patients, $XX that $XX we And is sites makes the we XXX lower sites, which if XX design. And trial the would really could so a I trial terms this a patients good I million. say maybe We’ve guess to part guiding or maybe think I start. key XX delivery, in in with a could think convection-enhanced of this sense, think I running the of probably a for previously a get lower terms of timing, trial. finally those months,

I outcome the looking could on at but is, clinical XX-month XX kind what it Just follow-up we’re a XX take is XX to benefit reasonable. think Depending the XX to months, of period. and

XX to XX trial a closer lasts months. at months, looking we’re to hopefully So XX that

of what all thinking what dependent to this to the we’re kind on ranges going that’s So that says. be say, and FDA giving is you

Marc Hedrick

other questions? any there are Gretchen,

Operator

No further questions over phone. the

Marc Hedrick

Thank Gretchen, you, Thanks. and Andrew.

good that so and you you. and those want version. Board, of listening on the and everybody have and broader recorded your that our very on close, thank to Thank just employees the on consultants for for trust us to joined of again and physicians And a participation once to members I like team, you work our thank the that the are the I we Thank course evening. patients just behalf much forth, with the us. call So our of that to say

Operator

This and conference you. time, Thank today’s day. line Please does at conclude disconnect your a call. this have wonderful

Plus Therapeutics (PSTV) 22 Apr 222022 Q1 Earnings call transcript